title: Region-specific neuroprotective effect of ZM 241385 towards glutamate uptake inhibition in cultured neurons.
abstract: Active uptake by neurons and glial cells is the main mechanism for maintaining extracellular glutamate at low, non-toxic concentrations. Adenosine A(2A) receptors regulate extracellular glutamate levels by acting on both the release and the uptake of glutamate. The aim of this study was to evaluate whether the inhibition of the effects of glutamate uptake blockers by adenosine A(2A) receptor antagonists resulted in neuroprotection. In cortical and striatal neuronal cultures, the application of l-trans-pyrrolidine-2,4-dicarboxylic acid (PDC, a transportable competitive inhibitor of glutamate uptake), induced a dose-dependent increase in lactate dehydrogenase (LDH) levels, an index of cytotoxicity. Such an effect of PDC was significantly reduced by pre-treatment with the adenosine A(2A) receptor antagonist ZM 241385 (50 nM) in striatal, but not cortical, cultures. The protective effects of ZM 241385 were specifically due to a counteraction of PDC effects, since ZM 241385 was totally ineffective in preventing the cytotoxicity induced by direct application of glutamate to cultures. These results indicate that adenosine A(2A) receptor antagonists prevent the toxic effects induced by a transportable competitive inhibitor of glutamate uptake, that such an effect specifically occurs in the striatum and that it does not depend on a direct blockade of glutamate-induced toxicity.
authors.affiliation: Department of Therapeutic Research and Medicines Evaluation, Istituto Superiore di Sanità, Viale Regina Elena, 299, 00161, Rome, Italy.
authors.forename: Rita
authors.initials: R
authors.lastname: Pepponi
authors.forename: Antonella
authors.initials: A
authors.lastname: Ferrante
authors.forename: Roberta
authors.initials: R
authors.lastname: Ferretti
authors.forename: Alberto
authors.initials: A
authors.lastname: Martire
authors.forename: Patrizia
authors.initials: P
authors.lastname: Popoli
mesh_terms: D058917:Adenosine A2 Receptor Antagonists; D000818:Animals; D001667:Binding, Competitive; D001692:Biological Transport / Q000187:drug effects; D032701:Biomimetics; D015153:Blotting, Western; D002478:Cells, Cultured; D002540:Cerebral Cortex / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D003998:Dicarboxylic Acids / Q000633:toxicity; D005260:Female; D005786:Gene Expression Regulation / Q000187:drug effects; D018698:Glutamic Acid / Q000378:metabolism* / Q000633:toxicity; D017072:Neostriatum / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D009474:Neurons / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism* / Q000473:pathology; D018696:Neuroprotective Agents / Q000494:pharmacology*; D009928:Organ Specificity; D011247:Pregnancy; D011759:Pyrrolidines / Q000633:toxicity; D051381:Rats; D043705:Receptor, Adenosine A2A / Q000378:metabolism; D013379:Substrate Specificity; D014227:Triazines / Q000494:pharmacology*; D014230:Triazoles / Q000494:pharmacology*
chemical_list: D058917:Adenosine A2 Receptor Antagonists; D003998:Dicarboxylic Acids; D018696:Neuroprotective Agents; D011759:Pyrrolidines; D043705:Receptor, Adenosine A2A; D014227:Triazines; D014230:Triazoles; C097270:ZM 241385; D018698:Glutamic Acid; C083486:pyrrolidine-2,4-dicarboxylic acid